Type II hyperprolinemia. Delta1-pyrroline-5-carboxylic acid dehydrogenase deficiency in cultured skin fibroblasts and circulating lymphocytes.
about
The three-dimensional structural basis of type II hyperprolinemiaCloning, characterization, and expression of cDNAs encoding human delta 1-pyrroline-5-carboxylate dehydrogenaseFunctional consequences of PRODH missense mutationsGenetic evidence for a common enzyme catalyzing the second step in the degradation of proline and hydroxyprolineStructural Determinants of Oligomerization of Δ1-Pyrroline-5-Carboxylate Dehydrogenase: Identification of a Hexamerization Hot SpotStructural basis of substrate selectivity of Δ1-pyrroline-5-carboxylate dehydrogenase (ALDH4A1): Semialdehyde chain lengthStructural Studies of Yeast Δ 1 -Pyrroline-5-carboxylate Dehydrogenase (ALDH4A1): Active Site Flexibility and Oligomeric StateDevelopment of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity.Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1.Gyrate atrophy of the choroid and retina: deficiency of ornithine aminotransferase in transformed lymphocytes.Type II hyperprolinaemia in a pedigree of Irish travellers (nomads)Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism.Crystallization and avoiding the problem of hemihedral twinning in crystals of Delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus.Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family.Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics.Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.Behavioral and neurochemical effects of proline.Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia.
P2860
Q24315802-5B5F5F50-5968-44B6-8769-7CED4CCA41CDQ24336950-3AE8A80F-A795-49AD-9730-A5BFDB4D69B2Q24338650-174EA849-AF36-4E2D-B50A-229217ACCC4AQ24598296-DFC2A66F-84C3-4583-9C06-0315B456CADAQ27678545-A7FCEF44-98E3-48D8-B0D9-C1999E42A9EEQ27679462-B3D0CE1D-7728-481E-9FD8-CF00DDA8F538Q27681620-41F4C179-1499-4248-AF69-2428C10E03F7Q33707099-B40EAEBC-EB5F-4BCF-80C3-9234D19C694DQ34934231-69D5B421-C110-4200-AAE2-C859A0FEBD28Q35062416-5FFDBBAD-B19B-43F4-B28E-0F301C2FF7E0Q35626334-89370A60-9D7C-4D7F-9722-7DBBF9064A9CQ35828024-255775F2-36CD-47BF-AE81-B61A637B87F3Q35950708-70338969-AB25-4DE1-BFBE-A159503D5904Q36475176-75D90837-C867-4D61-BF59-416FC6FE1406Q36662870-27C90540-25EF-4445-9CB5-0EAC48B589B8Q37706367-3C893975-A32F-4BF4-BB3E-E49431FB10C8Q37885227-8D10F0C3-1560-442C-A096-58CF6EE9C666Q54672211-E6FD89E0-8C4A-4F14-BDD7-575DC93A77E0
P2860
Type II hyperprolinemia. Delta1-pyrroline-5-carboxylic acid dehydrogenase deficiency in cultured skin fibroblasts and circulating lymphocytes.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@ast
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@en
type
label
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@ast
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@en
prefLabel
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@ast
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@en
P2093
P2860
P356
P1476
Type II hyperprolinemia. Delta ...... s and circulating lymphocytes.
@en
P2093
P2860
P304
P356
10.1172/JCI108506
P407
P577
1976-09-01T00:00:00Z